HER2-positive Tumours and Clinical Implications by Dr Richard de Boer

This publication is a summary of a recent presentation by Dr Richard de Boer, a medical
oncologist at the Royal Melbourne Hospital, Victoria, Australia. He spoke to a panel of
medical oncologists, oncology specialists and other health professionals, in Hamilton,
Auckland and Wellington in November 2009, regarding risk prediction of patients with
small node-negative HER2-positive breast cancers and how to tailor their therapy
accordingly. He also discussed the use of adjuvant chemotherapy in high-risk breast
cancer patients, focusing on the role of dose-dense therapy in the treatment of early-
stage breast cancer.